Finbar Larkin - 03 Mar 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Footnote F1

These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

Footnote F2

Includes 72 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022.

Footnote F3

Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Footnote F4

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Footnote F5

These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vested over four years measured from the grant date, May 3, 2013, with 1/4th vesting on April 9, 2014 and the remainder vesting in 36 equal monthly installments thereafter. The option is fully vested and exercisable as of the date of this Form.